Blue Light Therapy For Melasma Patients Melasma, a common skin pigmentation condition, presents as distinctive brown spots on the face, notably affecting individuals with darker skin tones. Although the exact causes remain elusive, factors such as solar radiation, genetics, and hormonal fluctuations are believed to play pivotal roles. Solar radiation, including
Oncology
Cabozantinib Therapy In Hepatocellular Carcinoma
Cabozantinib Therapy In Hepatocellular Carcinoma Hepatocellular carcinoma (HCC) is a predominant form of liver cancer, accounting for approximately 90% of cases. Unfortunately, it carries a grim prognosis, with a median survival rate ranging from 6 to 18 months. Historically, sorafenib had been the established first-line therapy for HCC. However, in recent
PD-1/L1 Inhibitors: Treatment Efficacy In Urothelial Carcinoma
PD-1/L1 Inhibitors: Treatment Efficacy In Urothelial Carcinoma Overview Programmed cell death‐1/ligand 1 (PD-1/PD-L1) inhibitors represent a novel therapeutic approach for advanced urothelial carcinoma, prompting the need for a comparative assessment of their effectiveness and safety in comparison to traditional chemotherapy. To address this, a comprehensive meta-analysis of randomized controlled trials conducted until
Skin Lightening: Topical Approaches To Treatment
Skin Lightening: Topical Approaches To Treatment Overview The recent removal of hydroquinone from over-the-counter skin lightening products has created a demand for modern formulations that effectively address skin pigmentation issues. A successful skin lightening formulation should be non-irritating to prevent post-inflammatory hyperpigmentation, penetrate effectively to reach the epidermal/dermal junction, incorporate anti-inflammatory ingredients,
Encapsulated Papillary Carcinoma Membrane Characteristics
Encapsulated Papillary Carcinoma Membrane Characteristics Overview This study focused on encapsulated papillary carcinoma (EPC), a type of breast carcinoma characterized by a thick fibrous capsule-like structure surrounding the tumor, often interpreted as a thickened basement membrane (BM). The primary objective was to investigate the geometric properties of the EPC capsule and determine
Ibrutinib Treatment In Waldenström Macroglobulinemia
Ibrutinib Treatment In Waldenström Macroglobulinemia Waldenström macroglobulinemia (WM) is a rare type of non-hogdkins lymphoma driven by the gene mutation MYD88L265P. Ibrutinib, the first approved treatment, is effective but can cause side effects. A study found that 27% of WM patients needed to reduce Ibrutinib doses due to side effects like
Eyelid Carcinoma (SGC): A Tool To Predict Recurrence
Eyelid Carcinoma (SGC): A Tool To Predict Recurrence Overview Eyelid sebaceous gland carcinoma (SGC) is a highly malignant condition with a significant recurrence risk. This study aimed to create a predictive nomogram for SGC recurrence based on risk factors. A retrospective study involving 391 patients from one hospital (304) and grassroots hospitals (87)
Stomach Cancer: A Meta-Analysis Of Robotic Surgery Complications
Stomach Cancer: A Meta-Analysis Of Robotic Surgery Complications Gastric or stomach cancer prevalence varies significantly around the world, with higher rates in Asia, Africa, South America, and Eastern Europe. However, in the United States, stomach cancer is a growing concern due to its increased occurrence in the elderly population and its
Chemotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma
Chemotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma Overview This study aimed to investigate serious chemotherapy-induced thrombocytopenia (CIT) in nasopharyngeal carcinoma (NPC), focusing on its incidence, consequences, and predictors. The retrospective analysis of NPC patients from 2013 to 2015 revealed a 5.21% incidence of serious chemotherapy-induced thrombocytopenia. Patients experiencing severe thrombocytopenia had notably worse long-term prognoses,
Endocrine Therapy Outcomes In Senior Breast Cancer Patients
Endocrine Therapy Outcomes In Senior Breast Cancer Patients Overview This study investigated the management of early-stage, hormone receptor-positive, and human epidermal growth factor receptor 2 negative (HR+/HER2−) breast cancer in older women aged 70 to 90 years between 2010 and 2015. Specifically, it focused on patients who underwent lumpectomy and omitted radiation
